Effect of Ketamine on Intraoperative Motor Evoked Potentials
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Nov 14, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of ketamine, a medication commonly used for anesthesia, on motor function during surgery for patients having spinal procedures. Specifically, researchers want to see how different doses of ketamine impact the signals that show how well the nerves and muscles are working while patients undergo thoracolumbar spinal fusions. This trial is open to adults aged 18 and older who are scheduled for these types of surgeries, but those with certain health conditions, like severe high blood pressure or a history of heart problems, cannot participate.
If you decide to join the trial, you will receive a standard anesthetic for your surgery, and along with that, you’ll get increasing doses of ketamine. The medical team will measure your motor responses at each dose to see how ketamine affects your nerve and muscle function. It's important to know that this trial is currently recruiting participants, and your involvement could help improve our understanding of how to enhance surgical outcomes for spinal surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (\>18 years of age) undergoing posterior spinal fusions.
- Exclusion Criteria:
- • Sensitivity or allergy to ketamine.
- • Schizophrenia or other psychotic conditions
- • Uncontrolled hypertension with systolic blood pressure greater than 180 mmHg
- • Myocardial Infarction
- • Large vascular aneurysms
- • Patients on ketamine as outpatient therapy.
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
San Francisco, California, United States
Patients applied
Trial Officials
Marc Buren, MD
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported